Overall Savings Generated by Generics and Biosimilars
## Topline Findings

### Total Savings from Generics and Biosimilars

- Total generic and biosimilar savings in 2022: $408 billion
- Total generic and biosimilar savings for the past ten years: $2.9 trillion
- Total generic and biosimilar savings in Medicare in 2022: $130 billion ($2,563 per beneficiary)
- Total generic and biosimilar savings in the commercial market in 2022: $194 billion
- Share of total U.S. prescriptions filled: 90 percent
- Share of total U.S. prescription drug spending: 17.5 percent
- Share of total U.S. health care spending: 1.5 percent

### Generic Savings

- Average generic copay: $6.16
- Average brand-name copay: $56.12
- 92 percent of generics have a copay less than $20; 53 percent of brands have a copay less than $20

### Biosimilar Savings

- Savings in 2022: $9.4 billion
- Total savings since first biosimilar entry in 2015: $23.6 billion
- Total days of patient therapy since 2015: 694 million
- Incremental days of patient therapy that would not have occurred without biosimilar competition: 344 million

Annual Savings From Generic and Biosimilar Medicines

Biosimilars Are Delivering Savings and Expanding Patient Access

- **42** approved
- **36** marketed

**Biosimilar savings since 2015**

- **$23.6 BILLION**

Biosimilars have been used in more than **694 MILLION DAYS** of patient therapy and have resulted in more than **344 MILLION INCREMENTAL DAYS** of therapy.

Biosimilar competition is driving lower prices among biosimilars and their reference products.

Source: US FDA and AAM Commercial Assessment.
Savings and patient day data developed by the Biosimilars Council with IQVIA.
Generics and Biosimilars Are More Than 90% of Prescriptions but Less Than 18% of Spending

Source: IQVIA National Sales Perspective, June 2022.

![Bar Chart showing the percentage of prescriptions and spending from 2012 to 2022.](chart.png)
Generics are 1.5% of Total U.S. Health Care Spending

Savings by Category
## Top 10 Generic Products with Greatest Savings in 2022

<table>
<thead>
<tr>
<th>PRODUCTS</th>
<th>GENERIC ENTRY YEAR</th>
<th>BRAND PRE-EXPIRY PRICE (PER UNIT)</th>
<th>PRICE OF GENERIC EQUIVALENT 2020 (PER UNIT)</th>
<th>2021 SAVINGS ($BILLION)</th>
<th>PERCENT SAVINGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucophage</td>
<td>2001</td>
<td>$0.66</td>
<td>$0.04</td>
<td>$5.63</td>
<td>94%</td>
</tr>
<tr>
<td>Neurontin</td>
<td>2003</td>
<td>$1.02</td>
<td>$0.06</td>
<td>$7.60</td>
<td>95%</td>
</tr>
<tr>
<td>Lipitor</td>
<td>2010</td>
<td>$3.29</td>
<td>$0.08</td>
<td>$22.38</td>
<td>97%</td>
</tr>
<tr>
<td>Toprol XI</td>
<td>1993</td>
<td>$0.41</td>
<td>$0.06</td>
<td>$2.09</td>
<td>85%</td>
</tr>
<tr>
<td>Norvasc</td>
<td>2006</td>
<td>$1.54</td>
<td>$0.02</td>
<td>$7.92</td>
<td>99%</td>
</tr>
<tr>
<td>Zestril</td>
<td>1998</td>
<td>$0.67</td>
<td>$0.03</td>
<td>$3.18</td>
<td>96%</td>
</tr>
<tr>
<td>Cozaar</td>
<td>2009</td>
<td>$1.51</td>
<td>$0.08</td>
<td>$5.85</td>
<td>95%</td>
</tr>
<tr>
<td>Prilosec</td>
<td>2001</td>
<td>$3.31</td>
<td>$0.04</td>
<td>$12.87</td>
<td>99%</td>
</tr>
<tr>
<td>Amoxil</td>
<td>1993</td>
<td>$0.04</td>
<td>$0.03</td>
<td>$0.02</td>
<td>14%</td>
</tr>
<tr>
<td>Cephulac</td>
<td>1993</td>
<td>$0.02</td>
<td>$0.01</td>
<td>$0.03</td>
<td>41%</td>
</tr>
</tbody>
</table>

Source: IQVIA National Sales Perspectives, December 2022.
Specialty Generic and Biosimilar Savings Continue to Grow

## Savings by Condition

<table>
<thead>
<tr>
<th>CONDITION</th>
<th>TOTAL SAVINGS (PRIMARY CONDITION + COMORBIDITIES)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Disease</td>
<td>$104.5 Billion</td>
</tr>
<tr>
<td>Anxiety and Depression</td>
<td>$60.5 Billion</td>
</tr>
<tr>
<td>Diabetes</td>
<td>$59.5 Billion</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>$42.2 Billion</td>
</tr>
<tr>
<td>Allergies and Asthma</td>
<td>$11.3 Billion</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td>$8.9 Billion</td>
</tr>
<tr>
<td>Parkinson’s Disease</td>
<td>$6.4 Billion</td>
</tr>
<tr>
<td>Alzheimer’s Disease</td>
<td>$6.2 Billion</td>
</tr>
<tr>
<td>Chronic Obstructive Pulmonary Disease (COPD)</td>
<td>$6.1 Billion</td>
</tr>
</tbody>
</table>

2022 Generic and Biosimilar Savings by Payer

Source: IQVIA National Sales Perspective, June 2022.
Patient Out-of-Pocket Costs
Patients Pay More for Brands Than Generics

Fewer Than Half of Generics Are on Generic Tiers in Medicare

Source: Avalere. 57% of Generic Drugs Are Not on 2022 Part D Generic Tiers (January 2022).
Accessible at: https://avalere.com/insights/57-of-generic-drugs-are-not-on-2022-part-d-generic-tiers
Medicare Plans Are Making Patients Pay More for Generics

In 2011 and 2019...
Annual spending on select generic drugs by seniors in Medicare increased by 135%, even as the prices for those drugs fell 38%

Between 2017 and 2020...
The portion of seniors in Medicare forced to pay the full cost for at least one generic increased from 45% to 63%

Source: Avalere. Some Medicare Part D Beneficiaries Pay Full Price for Generic Drugs (July 2022).
Accessible at: https://avalere.com/insights/some-medicare-part-d-beneficiaries-pay-full-price-for-generic-drugs#:~:text=Summary,on%20the%20preferred%20brand%20tier; Association for Accessible Medicines. Patients Pay More When Generic Drugs Are Placed On Non-Generic Tiers, Even Though Prices for Generics Are Going Down (October 2022). Accessible at: https://accessiblemeds.org/resources/blog/patients-pay-more-when-generic-drugs-are-placed-non-generic-tiers-even-though-0
New Generic Savings
Savings from New Generic and Biosimilar Competition Are Growing

Medicare Plans Are Particularly Slow to Cover New Generics

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M</td>
<td>C</td>
<td>M</td>
<td>C</td>
<td>M</td>
<td>C</td>
<td>M</td>
</tr>
<tr>
<td>2016</td>
<td>22%</td>
<td>46%</td>
<td>31%</td>
<td>68%</td>
<td>63%</td>
<td>72%</td>
<td>58%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>60%</td>
<td>76%</td>
<td>62%</td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td></td>
<td>12%</td>
<td>58%</td>
<td>25%</td>
<td>73%</td>
<td>58%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>65%</td>
<td>76%</td>
<td>65%</td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
<td>17%</td>
<td>39%</td>
<td>27%</td>
<td>49%</td>
<td>54%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>51%</td>
<td>59%</td>
<td>54%</td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>72%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>72%</td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>21%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>41%</td>
</tr>
<tr>
<td>2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23%</td>
</tr>
</tbody>
</table>

Medicare Part D (M) | Commercial (C)

Biosimilars
U.S. Biosimilars Market
As of August 2023

Source: Food and Drug Administration. Biosimilar Product Information (August 2023)
Accessible at: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
Launch dates evaluated through AAM assessment

**A high concentrate (March 2023) and low concentrate (October 2018) version are approved.
***A high concentrate (August 2022) and low concentrate (July 2019) version are approved.
Biosimilar Savings Continue to Increase

Source: IQVIA National Sales Perspective, December 2022
Biosimilars Are Now a Core Element of Patient Care

Total Days of Therapy for Patients on Biosimilars: 694 MILLION

Additional Patient Days Due to the Availability of Biosimilars: 344 MILLION

Source: IQVIA analysis of defined daily dose information and product volume.
Biosimilar Market Share Remains Less Than 20%

Biosimilars Consistently Drive Down Costs

Source: Centers for Medicare and Medicaid Services. Medicare Average Sales Price File (August 2022)
Biosimilars Are Reducing Spending on Autoimmune Therapy

PBM

Of the commercially insured patients prescribed Semglee, only 55% were filled.
Biosimilars Are Reducing Spending on Autoimmune Therapy